Keytruda combination hits primary endpoint in a rare form of gastric cancer
Merck’s Keytruda notched another positive set of data, this time in a rare cancer of the esophagus that sets up the company to receive full …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
